These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 7511766)

  • 21. Control of renal medullary blood flow by vasopressin V1 and V2 receptors.
    Nakanishi K; Mattson DL; Gross V; Roman RJ; Cowley AW
    Am J Physiol; 1995 Jul; 269(1 Pt 2):R193-200. PubMed ID: 7631893
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Acute hypertension after nitric oxide synthase inhibition is mediated primarily by increased endothelin vasoconstriction.
    Banting JD; Friberg P; Adams MA
    J Hypertens; 1996 Aug; 14(8):975-81. PubMed ID: 8884552
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Renal vasoconstriction by vasopressin V1a receptors is modulated by nitric oxide, prostanoids, and superoxide but not the ADP ribosyl cyclase CD38.
    Moss NG; Kopple TE; Arendshorst WJ
    Am J Physiol Renal Physiol; 2014 May; 306(10):F1143-54. PubMed ID: 24623148
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Interaction between V1 and V2 effects in hemodynamic response to vasopressin in dogs.
    Liard JF
    Am J Physiol; 1990 Feb; 258(2 Pt 2):H482-9. PubMed ID: 2137987
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Arginine vasopressin-mediated stimulation of nitric oxide within the rat renal medulla.
    Park F; Zou AP; Cowley AW
    Hypertension; 1998 Nov; 32(5):896-901. PubMed ID: 9822450
    [TBL] [Abstract][Full Text] [Related]  

  • 26. DDAVP (1-desamino-8-D-arginine vasopressin): an antagonist of the pressor action of endogenous vasopressin?
    Derkx FH; Man in 't Veld AJ; Jones R; Reid JL; Schalekamp MA
    J Hypertens Suppl; 1983 Dec; 1(2):58-61. PubMed ID: 6400119
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Vasodilatory effect of arginine vasopressin is mediated by nitric oxide in human forearm vessels.
    Tagawa T; Imaizumi T; Endo T; Shiramoto M; Hirooka Y; Ando S; Takeshita A
    J Clin Invest; 1993 Sep; 92(3):1483-90. PubMed ID: 8376600
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Receptor subtypes involved in relaxation and contraction by arginine vasopressin in canine isolated short posterior ciliary arteries.
    Okamura T; Toda M; Ayajiki K; Toda N
    J Vasc Res; 1997; 34(6):464-72. PubMed ID: 9425999
    [TBL] [Abstract][Full Text] [Related]  

  • 29. In vivo diuretic actions of renal vasopressin V1 receptor stimulation in rats.
    Ledderhos C; Mattson DL; Skelton MM; Cowley AW
    Am J Physiol; 1995 Mar; 268(3 Pt 2):R796-807. PubMed ID: 7900923
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Renal versus hindquarter hemodynamic responses to vasopressin in conscious rats.
    Harrison-Bernard LM; Brizzee BL; Clifton GG; Walker BR
    J Cardiovasc Pharmacol; 1990 Nov; 16(5):719-26. PubMed ID: 1703592
    [TBL] [Abstract][Full Text] [Related]  

  • 31. L-NAME antagonizes vasopressin V2-induced vasodilatation in dogs.
    Liard JF
    Am J Physiol; 1994 Jan; 266(1 Pt 2):H99-106. PubMed ID: 8304528
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Central cardiovascular effects of AVP and AVP analogs with V1, V2 and 'V3' agonistic or antagonistic properties in conscious dog.
    Noszczyk B; Lon S; Szczepańska-Sadowska E
    Brain Res; 1993 Apr; 610(1):115-26. PubMed ID: 8518919
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Vasodilation induced by vasopressin V2 receptor stimulation in afferent arterioles.
    Tamaki T; Kiyomoto K; He H; Tomohiro A; Nishiyama A; Aki Y; Kimura S; Abe Y
    Kidney Int; 1996 Mar; 49(3):722-9. PubMed ID: 8648913
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Nitric oxide, but not vasopressin V2 receptor-mediated vasodilation, modulates vasopressin-induced renal vasoconstriction in rats.
    Loichot C; Cazaubon C; De Jong W; Helwig JJ; Nisato D; Imbs JL; Barthelmebs M
    Naunyn Schmiedebergs Arch Pharmacol; 2000 Mar; 361(3):319-26. PubMed ID: 10731046
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effects of V1- and V2-vasopressin (AVP) antagonists on the pressor, AVP and atrial natriuretic peptide responses to a hypertonic saline infusion in conscious anephric rats.
    Ota K; Kimura T; Inoue M; Funyu T; Shoji M; Sato K; Ohta M; Yamamoto T; Abe K
    Eur J Endocrinol; 1995 Jul; 133(1):127-32. PubMed ID: 7627334
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Role of vasopressin in renal vascular changes with hypoxemia and hypercapnic acidosis in conscious dogs.
    Rose CE; Ragsdale NV; Carey RM
    Am J Physiol; 1990 Oct; 259(4 Pt 2):R690-702. PubMed ID: 2145777
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Mechanisms underlying arginine vasopressin-induced relaxation in monkey isolated coronary arteries.
    Okamura T; Ayajiki K; Fujioka H; Toda N
    J Hypertens; 1999 May; 17(5):673-8. PubMed ID: 10403611
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Inhibition of renal nitric oxide synthesis with NG-monomethyl-L-arginine and NG-nitro-L-arginine.
    Naess PA; Kirkebøen KA; Christensen G; Kiil F
    Am J Physiol; 1992 Jun; 262(6 Pt 2):F939-42. PubMed ID: 1535755
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effect of L-NG-nitro-arginine, inhibitor of nitric oxide synthesis, on autoregulation of renal blood flow in dogs.
    Kiyomoto H; Matsuo H; Tamaki T; Aki Y; Hong H; Iwao H; Abe Y
    Jpn J Pharmacol; 1992 Feb; 58(2):147-55. PubMed ID: 1507520
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Role of nitric oxide in vasopressinergic pulmonary vasodilatation.
    Russ RD; Walker BR
    Am J Physiol; 1992 Mar; 262(3 Pt 2):H743-7. PubMed ID: 1558183
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.